Argent Trust Co Buys 2,125 Shares of Zoetis Inc. (NYSE:ZTS)

by · The Cerbat Gem

Argent Trust Co boosted its position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 10.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 22,902 shares of the company’s stock after purchasing an additional 2,125 shares during the quarter. Argent Trust Co’s holdings in Zoetis were worth $3,970,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of ZTS. Webster Bank N. A. increased its position in shares of Zoetis by 89.1% in the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after buying an additional 82 shares in the last quarter. Neo Ivy Capital Management bought a new stake in shares of Zoetis in the fourth quarter worth about $40,000. LRI Investments LLC acquired a new stake in shares of Zoetis during the first quarter worth about $43,000. Hazlett Burt & Watson Inc. lifted its holdings in shares of Zoetis by 60.7% during the 1st quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock valued at $46,000 after purchasing an additional 102 shares in the last quarter. Finally, Central Valley Advisors LLC bought a new position in shares of Zoetis during the 2nd quarter valued at about $49,000. Institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

ZTS has been the subject of a number of research reports. Piper Sandler increased their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $200.00 target price on shares of Zoetis in a research note on Tuesday, August 27th. Finally, BTIG Research boosted their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $217.11.

Read Our Latest Report on Zoetis

Zoetis Stock Performance

NYSE ZTS opened at $195.74 on Wednesday. The firm has a market capitalization of $88.68 billion, a P/E ratio of 37.71, a price-to-earnings-growth ratio of 2.98 and a beta of 0.88. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The firm’s fifty day moving average price is $183.65 and its two-hundred day moving average price is $174.15. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92.

Zoetis (NYSE:ZTS – Get Free Report) last issued its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. During the same period in the prior year, the firm earned $1.41 EPS. Zoetis’s quarterly revenue was up 8.3% compared to the same quarter last year. As a group, research analysts anticipate that Zoetis Inc. will post 5.84 EPS for the current year.

About Zoetis

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Further Reading

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).